What do functional genomics tell us about pathogenesis of AML?

Area of Science:

• Hematology
• Oncology
• Genomics

Background:

• Molecular genetic abnormalities are crucial in acute myeloid leukemia (AML) pathogenesis.
• Genetic factors alone do not fully account for drug resistance or sensitivity in AML.
• Tumor microenvironment components, such as tumor-associated macrophages, influence AML progression.

Purpose of the Study:

• To comprehensively analyze genetic mutations in AML samples.
• To functionally test the sensitivity of AML cells to a wide range of drugs.
• To identify gene signatures and non-genetic factors impacting AML phenotypes and treatment outcomes.

Main Methods:

• Multicenter sequencing of acute myeloid leukemia (AML) patient samples.
• Functional drug screening of AML cells against over 120 therapeutic agents.
• Development of disease models integrating genetic data with drug response.
• Analysis of gene expression profiles to identify predictive signatures.

Main Results:

• Established correlations between specific mutations, AML phenotypes, and drug sensitivities.
• Identified gene signature profiles that may guide treatment selection.
• Demonstrated that factors beyond genetic mutations, including the tumor microenvironment, are critical in AML pathogenesis.

Conclusions:

• Genetic profiling is essential but insufficient for predicting AML treatment response.
• The tumor microenvironment, particularly tumor-associated macrophages, represents a potential therapeutic target in AML.
• Integrating genetic and non-genetic insights is key to advancing AML treatment strategies.